Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kaye

Showing results (831-840 of 853) with videos related to

Pageof 86
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancerBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
BMJ Open Ophthalmology|September 20, 2023
Preoperative surgeon evaluation of corneal endothelial status: the Viability Control of Human Endothelial Cells before Keratoplasty (V-CHECK) study protocolMatteo Airaldi, Yalin Zheng, Francesco Aiello, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Cancer Research|April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancerGerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study groupK Fizazi, S Tjulandin, R Salvioni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
EMBO Molecular Medicine|March 12, 2021
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancerMichal M Hoppe, Patrick Jaynes, Joanna D Wardyn, et al.
Pageof 86

Showing results (831-840 of 853) with videos related to

Sort By:
Pageof 86
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancerBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
BMJ Open Ophthalmology|September 20, 2023
Preoperative surgeon evaluation of corneal endothelial status: the Viability Control of Human Endothelial Cells before Keratoplasty (V-CHECK) study protocolMatteo Airaldi, Yalin Zheng, Francesco Aiello, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Cancer Research|April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancerGerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study groupK Fizazi, S Tjulandin, R Salvioni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
EMBO Molecular Medicine|March 12, 2021
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancerMichal M Hoppe, Patrick Jaynes, Joanna D Wardyn, et al.
Pageof 86